Market Newsdesk

BEIJING and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ — Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma.

Glioma is a broad term describing neuroepithelial tumors originating from glial cells of the central nervous system, including astrocytic tumors such as glioblastomas (GBM). GBM is one of the most aggressive primary brain tumors and has median survival of 12 to 15 months, despite advances in surgery, chemotherapy, and radiation therapy¹.  Gan & Lee’s current clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is investigating the treatment of advanced solid tumors which has the potential to provide physicians and patients with a much-needed treatment option.

“The EMA’s positive decision for GLR2007’s orphan drug designation is another milestone in the clinical development program as this compound was also recently granted ODD by the FDA,” Dr. Michelle Mazuranic, Head of Global Medical Affairs, Gan & Lee.  The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining market approval.

Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products. To qualify, an investigational medicine must be intended to treat a seriously debilitating or life-threatening condition that affects fewer than five in 10,000 people in the EU, and there must be sufficient non-clinical or clinical data to suggest the investigational medicine may produce clinically relevant outcomes and the potential for significant benefit over currently approved products. The EMA orphan drug designation can provide companies with clinical protocol assistance, differentiated evaluation procedures for Health Technology Assessments in certain countries, access to a centralized marketing authorization procedure valid in all EU member states, and reduced regulatory fees. After being granted marketing approval, compounds with orphan designation are eligible for 10 years of market exclusivity.

About Gan & Lee

Gan & Lee successfully developed the first Chinese domestic biosynthetic human insulin. The company has five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin®), fast-acting aspart injection (Rapilin™), mixed protamine zinc lispro injection (25R) (Prandilin®25), aspart 30 injection (Rapilin™30), reusable insulin injection pen (GanleePen™), and disposable pen needle (Ganlee Fine™).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance Gan & Lee’s goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities to treat various forms of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. For more information, please contact [email protected].

References

1. Galanis E, et. al. https://doi.org/10.1200/JCO.2005.23.622

Contact: Gina Antonucci, #: 888-288-5395, [email protected]

 

 

View original content:http://www.prnewswire.com/news-releases/gan–lee-receives-ema-orphan-drug-designation-for-phase-i-drug-candidate-glr2007-for-the-treatment-of-glioma-301262904.html

SOURCE Gan & Lee Pharmaceuticals Co., Ltd.

GÖTEBORG, Sweden, April 6, 2021 /PRNewswire/ — On Wednesday April 21, 2021, 08:00 am (CET), Castellum will publish the interim report January-March 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 09:00 am (CET) on the same date.

The Year-end report 2020 will be presented during the teleconference which will be hosted by Castellum’s CEO Henrik Saxborn and CFO Ulrika Danielsson. The presentation will also include a Q&A session and will be held in English.

To participate in the teleconference, please dial in on any of the telephone numbers below at least ten minutes before the teleconference:

You can access the presentation and the conference via the streaming link below: https://financialhearings.com/event/13288

The Year-end report 2020 and presentation will be available on castellum.se:
https://www.castellum.se/en/Investorrelations/financial-reports/

For further information, please contact:

Ulrika Danielsson, CFO, Castellum AB, phone +46 706 47 12 61

About Castellum

Castellum is one of the Nordic region’s largest listed real estate companies with a property value of SEK 103 billion. We are active in 14 Swedish growth regions as well as in Copenhagen and Helsinki. Every day, 250,000 people go to work in our premises. We develop flexible workplaces and logistics solutions with a lettable area of 4.4 million square meters. One of our sustainability goals is to be entirely climate neutral by 2030. Castellum is the only Nordic real estate company selected by the Dow Jones Sustainability Index (DJSI). The Castellum share is listed on the Nasdaq Stockholm Large Cap.

Beyond expectations.
www.castellum.se

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

 

View original content:http://www.prnewswire.com/news-releases/castellums-interim-report-january-march-2021-to-be-published-on-april-21-2021–invitation-to-teleconference-301262897.html

SOURCE Castellum

PHILADELPHIA, April 6, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) (the “Company”) today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior secured notes due 2026 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.

The Notes are expected to bear interest that will be payable semiannually. The Notes will mature in April 2026, unless earlier redeemed or repurchased in accordance with their terms. The Notes will be secured by first priority liens on substantially all of the assets of the Company and the guarantors, other than working capital assets pledged to secure the Company’s asset-backed credit facility, as to which the Notes will be secured on a second lien basis. The final terms of the Notes will be determined by market conditions and other factors and there is no guarantee that the Notes offering will be completed.

The Company intends to use the net proceeds of the Notes offering, together with other borrowings under a separate anticipated junior lien credit facility and cash on hand, to repay its existing term loan indebtedness and to pay certain related fees and expenses.

This press release is neither an offer to sell nor a solicitation of an offer to buy the Notes, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

The Notes have not been and will not be registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The offering of the Notes is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company’s website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statements, including, but not limited to, the proposed offering of the Notes, the anticipated terms and the timing and closing of the Notes, the expected use of the net proceeds from this transaction, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or regulatory approvals or actions, the ability to successfully manufacture and commercialize products upon approval, including acquired products, and the Company’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the Company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.  These forward-looking statements represent the Company’s judgment as of the date of this news release.  The Company disclaims any intent or obligation to update these forward-looking statements.

Contact:         
Robert Jaffe
Robert Jaffe Co., LLC
(424) 288-4098

View original content to download multimedia:http://www.prnewswire.com/news-releases/lannett-announces-offering-of-350-million-senior-secured-notes-due-2026-301262895.html

SOURCE Lannett Company, Inc.

ERIE, Pa., April 6, 2021 /PRNewswire/ — Whether it’s a spare bedroom, the basement or extra space above the garage, there are lots of reasons to personalize “bonus” space in your home. Whatever your motivation, Consumer Reports estimates adding a flex or double-duty room can potentially boost your home’s value by 4 to 6 percent.

If you are looking for ideas, Erie Insurance has five suggestions to create a bonus room to brag about:

1.  Workout space: Make a home gym with rubber flooring, fitness equipment and free weights. Or mellow out and design your own yoga sanctuary. Either way, adding mirrors to a room can make a smaller space appear larger and help you check your form.
2. Kids playroom: Whether it’s for your own kids, grandkids or a home babysitting setup, the little ones will love having their own space. Houzz has this list of ideas for designing a playroom.
3. Arts and crafts room: Here’s your excuse to splurge on home organization accessories! Creative hobbies like sewing, painting, knitting or quilting require lots of supplies. A designated space can help you keep your creative focus. Get more hobby room inspiration in this list from HGTV.
4. Movie theatre: With a home theater, the whole family can enjoy the big-screen experience without the overpriced popcorn. The must-haves? A projector, comfy seating, dimmable lighting and a solid sound system. Amp up your next showing with this list of creative family movie night ideas.
5. Music room: Soundproofing makes at-home recordings sound cleaner – and keeps the neighbors happy, too. Whether you want a home recording studio or just a space to jam with friends, opt for bold, inspirational colors, mood lighting and lots of storage space. 

Whenever you tackle a major home improvement project, don’t forget to check in with your insurance agent. Major improvements that add value to your home often mean you need a higher limit on your homeowners insurance. Learn more about what makes our homeowners coverage different, or find a local ERIE agent to request a quote.

About Erie Insurance
According to A.M. Best Company, Erie Insurance Group, based in Erie, Pennsylvania, is the 11th largest homeowners insurer and 12th largest automobile insurer in the United States based on direct premiums written and the 16th largest property/casualty insurer in the United States based on total lines net premium written.  The Group, rated A+ (Superior) by A.M. Best Company, has nearly 6 million policies in force and operates in 12 states and the District of Columbia. Erie Insurance Group is a FORTUNE 500 company.

News releases and more information about Erie Insurance Group are available at www.erieinsurance.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/5-ideas-for-your-new-bonus-room-301261238.html

SOURCE Erie Insurance Group

• Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021

MONTRÉAL, April 6, 2021 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (“Ortho RTI” or the “Company“), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.

“The IND submission for our first ORTHO-R human trial is a key milestone for the Company. It brings us one step closer to the enrollment of our first patient, a recognized value creation event in our industry”, said Claude LeDuc, President and CEO of Ortho RTI. “There is a clear need for improved rotator cuff tear repair treatments, as estimates have put the re-tear (or non healing) rate at an average of 50%. With more than 600,000 patients undergoing rotator cuff surgery every year in the U.S., this represents an enormous commercial opportunity, and as demonstrated in 2020 by our GLP preclinical program results, we strongly believe that ORTHO-R can help address these significant unmet needs and meaningfully improve the success rate of these surgeries.”  

The Phase I/II clinical trial is a prospective, randomized, controlled and blinded study to evaluate the safety and efficacy of ORTHO-R + standard of care surgery vs standard of care surgery alone in rotator cuff tear repair. The clinical trial will enroll a total of 78 patients at 6 to 10 clinical sites throughout the U.S.  Enrollment is expected to begin in Q2 of 2021.

About ORTHO-R

ORTHO-R, a Chitosan-Platelet-Rich Plasma (PRP) hybrid implant, has been designated by the US FDA as a drug/biologic combination product. It is formulated and designed to augment the healing rate of occupational and sports related injuries to tendons, meniscus and ligaments. The physicochemical configuration of our proprietary Chitosan-based biopolymer matrix acts as a biodegradable mucoadhesive scaffold which chemically interacts with the PRP biologic components. Some of the benefits of this interaction between the drug/biologic combination are the significant increase in the residency time of the PRP bioactive material delivered at the surgically repaired site, and prolongation of the release of growth factors from PRP, enhancing the therapeutic effect with potential to significantly improve benefits to patients. ORTHO-R is directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.

About Rotator Cuff Injury 

The rotator cuff is the name given to the collection of four tendons that stabilize the shoulder joint. The tendons around the joint can suffer tears as a result of injury to the tendon or as a result of degeneration over time. Repetitive overhead activity is often associated with cuff tears. Symptoms include a dull, aching pain, and patients often suffer secondary symptoms including lack of sleep and weakness in the arms resulting from a lack of exercise. If conservative therapy is not successful, surgery will often be performed. The principal aim of surgical intervention is to reattach the torn tendon to the bone. The standard of care involves the use of suture anchors placed into the bone and the tendon then being held in place with sutures. There are 4 million Americans with rotator cuff injuries, and all are at risk for disability. It is estimated that 25% of U.S. adults over the age of 40 will develop a rotator cuff tear, with aging ‘weekend warriors’ escalating the problem.

About Ortho Regenerative Technologies Inc.

Ortho RTI is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant potential of our technology platform, Ortho RTI continues to assess new therapeutic target uses outside of the soft tissue repair field. Further information about Ortho RTI is available on the Company’s website at www.orthorti.com and on SEDAR at www.sedar.com. Also follow us on LinkedIn and Twitter.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Company’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ortho-regenerative-technologies-announces-submission-of-investigational-new-drug-application-for-ortho-r-301262538.html

SOURCE Ortho Regenerative Technologies Inc.

WILMINGTON, Del., April 6, 2021 /PRNewswire/ — Corteva, Inc. (NYSE: CTVA) today announced that it has appointed Dave Anderson as its new Executive Vice President & Chief Financial Officer (CFO), effective April 12, 2021. A highly experienced finance executive, Mr. Anderson has a track record of providing financial leadership in complex, global companies to support value creation. In this role, he succeeds Gregory R. Friedman who is retiring from Corteva, as previously announced.

Throughout his career, Mr. Anderson has focused on establishing finance functions that enable ongoing investment in growth initiatives while driving returns and value creation for shareholders. He spent more than a decade as CFO of Honeywell, through 2014. Since then, he has held the CFO role at other market-leading companies, with a focus on establishing strong finance functions, cost structures, capital allocation programs, and solid foundations for growth.          

James C. Collins, Jr., Corteva’s Chief Executive Officer, said, “Corteva has solid momentum and as we enter our next phase of growth, we are relentlessly focused on execution to drive substantial earnings increases and margin expansion. Dave brings a track record leading world-class finance functions at both established companies and startups and I look forward to capitalizing on his expertise as we take our strong organization to the next level, supporting our accelerated growth and innovation investments while maximizing productivity and returns.”

Mr. Anderson said, “Under Jim’s leadership Corteva has established its position as a global leader in agriculture and I look forward to working with him and the entire team. With a strong strategy in place, I am excited to apply my cumulative experience towards accelerating progress, helping to ensure that Corteva will capitalize fully on its competitive advantages, deliver best-in-class productivity through ERP implementation and other initiatives across the business, and drive value creation for its shareholders.”

Biography

Dave Anderson has had a multi-decade career as a finance leader across diverse industries with a track record of driving returns and value creation. Prior to today’s announcement, Mr. Anderson was Interim CFO at Criteo S.A., which he joined after serving as CFO and Chief Operating Officer at Nielsen Holdings plc. He previously served as EVP and CFO of Alexion Pharmaceuticals, which he joined following his tenure at Honeywell, from 2003-2014. Prior to that, he was the Chief Financial Officer for ITT, Inc., Newport News Shipbuilding Inc., and RJR Nabisco, Inc.  He also held various senior finance roles at the Quaker Oats Company, Kraft Food, Inc., and FMC Corp. He holds a B.S. in Economics from Indiana University and earned his M.B.A. at the University of Chicago’s Booth School, where he was a founding member and co-Chair of its CFO Forum. Mr. Anderson is currently a Board member of American Electric Power and previously a Board member of Cardinal Health.

About Corteva
Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that provides farmers around the world with the most complete portfolio in the industry – including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability. With some of the most recognized brands in agriculture and an industry-leading product and technology pipeline well positioned to drive growth, the Company is committed to working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva became an independent public company on June 1, 2019 and was previously the Agriculture Division of DowDuPont. More information can be found at www.corteva.com.

Follow Corteva on Facebook, Instagram, LinkedIn, Twitter and YouTube.

^{™ ®
℠} Trademarks and service marks of Corteva Agriscience and its affiliated companies.

Cautionary Statement About Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “goals”, “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “target,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s strategies for growth, capital allocation, and productivity savings are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, Corteva’s ability to competitively attract, develop and retain talent; employee turnover rates; restructurings; supplier disruptions and consolidations; and similar risks, any of which could have a material adverse effect on Corteva’s results. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: i) failure to obtain or maintain the necessary regulatory approvals for some Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products;  (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva’s products; (xi) impact of Corteva’s dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; failure to enforce; (xxii) risks related to COVID-19;  (xxiii) risks related to activist stockholders; (xxiv) Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements;  and (xxvii) other risks related to the Separation from DowDuPont. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.

View original content to download multimedia:http://www.prnewswire.com/news-releases/corteva-names-dave-anderson-evp–chief-financial-officer-301262467.html

SOURCE Corteva, Inc.

BEIJING, April 6, 2021 /PRNewswire/ — Suning.com (002024.SZ), China’s leading smart retail service provider and a Fortune Global 500 company owned by Suning Group, has launched a new home appliance trade-in scheme during its inaugural 2021 Product Upgrade Conference held on March 30 in Beijing. The new plan will see Suning.com subsidize 500 million product trade-ins and offer free home appliance testing and maintenance services.

In fact, Suning.com pioneered home appliance trade-in services starting in 2005. In 2009, when China introduced a national trade-in policy for home appliances, Suning.com responded immediately by further updating its services including setting up a reservation hotline and offering specialized consulting services in its brick-and-mortar stores. In the same year, China’s first batch of customers who benefited from the national trade-in policy were mostly Suning.com users. More than a decade on, the first batch of home appliances to benefit from the scheme are nearing the end of their product life-cycle — ushering in a new opportunity for the trade-in market.

Seamless cross-category upgrades, delivered in just one hour

During the conference, Hou Enlong, president of retail at Suning.com, unveiled the latest version of Suning.com’s 3C home appliance trade-in plan. Consumers can enjoy a streamlined upgrade process that encompasses old appliance removal, new appliance installation, price comparison, improved customer experience and more.

As part of its scheme, Suning.com will complete the delivery of a new home appliance while simultaneously removing the old appliance. This saves customers from needing to wait for a replacement machine or organize their own appliance removal. The scheme also supports cross-category trade-ins, which enables customers to swap an existing appliance in one category with an appliance in another, such as trading in a fridge for a washing machine.

With tens of thousands of stores nationwide, Suning.com can realize trade-ins in just 60 minutes. Customers can place an order online and enjoy rapid delivery to their doorstep, or head to their nearest store and complete the trade-in — both in as little as one hour. Suning.com also instantly completes a one-click valuation of the old appliance, then directly deducts this from the price of the new model for a seamless trade-in.

Suning.com has launched a new home appliance maintenance service in tandem with its trade-in scheme. Consumers can enjoy free maintenance services on-site, or schedule a complimentary at-home visit from a professional engineer.

Supporting change with action

Xiong Xiangyi, executive president of Liaowang Institute – the public policy research center at the National Center for Research (NCR), released its 2021 China Home Appliances Trade-in Annual Survey Report during the conference. He noted that the product upgrades are expected to become more popular in 2021. Due to the increasing awareness of trade-ins among Chinese consumers, 2021 is slated to be the first year where the industry sees an uptick in consumers swapping old appliances for upgraded products.

Home appliance trade-in policies have garnered significant attention as a result of their ability to reduce carbon footprint and support green consumption. The Report acknowledged that in the trade-in 2.0 era, government-led and company-sponsored programs will become more significant. Recognizing this, Suning.com has actively launched a number of trade-in benefits and subsidies — pioneering the green home appliance market of tomorrow.

As the leading company in recycled home appliances, Suning.com’s dual-line service upgrades are aligned with consumer demand for smart, high-quality household appliances. At the same time, Suning.com has developed its trade-in service to help promote recycling and upcycling within the industry.

View original content:http://www.prnewswire.com/news-releases/out-with-the-old-in-with-the-new-suning-subsidizes-500-million-product-trade-ins-and-offers-free-on-site-home-appliance-inspections-301262880.html

SOURCE Suning Group